ライフサイエンスコーパス: urokinase-type plasminogen activator

1 n through the expression of the receptor for urokinase type plasminogen activator.

2 ly enhances the activation of plasminogen by urokinase type plasminogen activator.

3 oteins intercellular adhesion molecule-1 and urokinase-type plasminogen activator.

4 iation, and this cleavage may be mediated by urokinase-type plasminogen activator.

5 of endothelial cell integrin alphavbeta3 and urokinase-type plasminogen activator.

6 but not thrombin, coagulation factor Xa, or urokinase-type plasminogen activator.

7 th factor 1, leukemia inhibitory factor, and urokinase-type plasminogen activator.

8 quent cell movement and migration by binding urokinase-type plasminogen activator.

9 a more effective inactivator of tPA than of urokinase-type plasminogen activator.

10 nt hK2, which readily activated single chain urokinase-type plasminogen activator.

11 U1) by costimulation with phorbol esters and urokinase-type plasminogen activator.

12 any previously reported variants of t-PA or urokinase-type plasminogen activator.

13 activities of matrix metalloproteinase-2 and urokinase-type plasminogen activator.

14 is the main inhibitor of the tissue type and urokinase type plasminogen activators.

15 the reactions of PAI-1 with tissue-type and urokinase-type plasminogen activators.

16 comitant increased expression of its target, urokinase-type plasminogen activator, a known tumor-asso

17 ts displayed moderately reduced single-chain urokinase-type plasminogen activator activation.

18 filtrates induce a 3- to 10-fold increase in urokinase-type plasminogen activator activity in mammary

19 t the effect of L-MIM involves a decrease in urokinase-type plasminogen activator activity.

20 greatly reduced the activity of both tPA and urokinase-type plasminogen activator after HI.

21 , leading to the up-regulation of macrophage urokinase type plasminogen activator and matrix metallop

22 and stimulated the expression of macrophage urokinase type plasminogen activator and MMP-9.

23 ibrinolytic cascade by colocalizing with the urokinase type plasminogen activator and receptor comple

24 Pdef also results in the down-regulation of urokinase-type plasminogen activator and activation of t

25 d secretion of matrix metalloproteinases and urokinase-type plasminogen activator and an increase in

26 at the translational level by eIF3e included urokinase-type plasminogen activator and apoptotic regul

27 ement with these findings, reduced levels of urokinase-type plasminogen activator and elevated levels

28 turn induced expression of VEGF, MMP-9, and urokinase-type plasminogen activator and increased migra

29 The urokinase-type plasminogen activator and its receptor (u

30 ation of collagen IV, and their secretion of urokinase-type plasminogen activator and its receptor.

31 associated with expression of high levels of urokinase-type plasminogen activator and low levels of T

32 The urokinase-type plasminogen activator and membrane-type M

33 dative phenotype of macrophages via enhanced urokinase-type plasminogen activator and MMP-9 expressio

34 cultures stimulates their expression of both urokinase-type plasminogen activator and MMP-9, and the

35 serpin inhibits tPA and, to a lesser extent, urokinase-type plasminogen activator and plasmin.

36 the expression of matrix metalloproteinases, urokinase-type plasminogen activator, and cytokines in h

37 While matrix metalloproteinases, urokinase-type plasminogen activator, and cytokines play

38 m via mechanisms involving both cell surface urokinase-type plasminogen activator, and interactions b

39 variant failed to activate the single-chain urokinase-type plasminogen activator, and the G221A and

40 sminogen, tissue-type plasminogen activator, urokinase-type plasminogen activator, and urokinase-type

41 the inhibition of interleukin (IL)-6, IL-8, urokinase-type plasminogen activator, and VEGF productio

42 activated receptor 2 (PAR2) and single-chain urokinase-type plasminogen activator are proteins that a

43 roduced plasminogen activators (i.e. tPA and urokinase-type plasminogen activator) are responsible fo

44 ng rate constant (klim) of RCL insertion for urokinase-type plasminogen activator at pH 6.2-8.0 and f

45 complex with the amino-terminal fragment of urokinase-type plasminogen activator (ATF), at the resol

46 n (FN)-1, plasminogen activator inhibitor-1, urokinase-type plasminogen activator, caveolin-1 and Slu

47 MMP-12 induction in plasminogen(Plg)-treated urokinase-type plasminogen activator-deficient macrophag

48 (6) integrin, called alpha(6)p, generated by urokinase-type plasminogen activator-dependent cleavage

49 promatrilysin to an active elastolysin via a urokinase-type plasminogen activator-dependent pathway.

50 Five proteases were identified: urokinase-type plasminogen activator, factor XII, protei

51 mice carrying a mouse major urinary protein-urokinase-type plasminogen activator fusion transgene.

52 mmune-deficient transgenic mice carrying the urokinase-type plasminogen activator gene driven by the

53 upon activation of PepO-bound plasminogen by urokinase-type plasminogen activator, generated plasmin

54 ombinant PSA failed to activate single chain urokinase-type plasminogen activator, in contrast to the

55 he expression of its downstream target gene, urokinase-type plasminogen activator, in metastatic panc

56 al (Beas2B) cells decreased basal as well as urokinase-type plasminogen activator-induced PAI-1 expre

57 Plasmin, generated by the endogenous urokinase-type plasminogen activator, is not an efficien

58 PAI-1), the primary inhibitor of tissue- and urokinase-type plasminogen activators, is considered a c

59 (ERK)1/2 activation, and decreases levels of urokinase-type plasminogen activator, known downstream e

60 immunodeficient BALB-DeltaRAG/gamma(c) -uPA (urokinase-type plasminogen activator) mice, freshly thaw

61 gonucleotides reduced the levels of ETS1 and urokinase-type plasminogen activator mRNAs.

62 icellular proteolytic cascades by activating urokinase-type plasminogen activator on the cell surface

63 in absence of ADAMTS13, after activation by urokinase-type plasminogen activator or the thrombolytic

64 in(i) acts specifically; it does not inhibit urokinase-type plasminogen activator, plasmin, chymotryp

65 cluding very low density lipoprotein (VLDL), urokinase-type plasminogen activator:plasminogen activat

66 gen activator precursor (PLAT; 2.8-fold) and urokinase-type plasminogen activator precursor (PLAU; 2.

67 The binding of the zymogenic form of urokinase-type plasminogen activator (pro-uPA) to its sp

68 e epsilon readily converted single-chain pro-urokinase-type plasminogen activator (pro-uPA/scuPA) int

69 an effect on the expression/function of the urokinase-type plasminogen activator protease uPA/uPAR s

70 The expression of urokinase type plasminogen activator receptor (uPAR) and

71 Circulating levels of soluble forms of urokinase-type plasminogen activator receptor (suPAR) ar

72 Recent studies describe soluble urokinase-type plasminogen activator receptor (suPAR) as

73 Relatively high plasma levels of soluble urokinase-type plasminogen activator receptor (suPAR) ha

74 Serum soluble urokinase-type plasminogen activator receptor (suPAR) is

75 Increased plasma level of soluble urokinase-type plasminogen activator receptor (suPAR) wa

76 ulin (beta-2 m), neopterin and suPAR soluble urokinase-type plasminogen activator receptor (suPAR) wa

77 In addition, Pdcd4 knockdown stimulates urokinase-type plasminogen activator receptor (u-PAR) an

78 The transcriptionally regulated urokinase-type plasminogen activator receptor (u-PAR) co

79 The urokinase-type plasminogen activator receptor (u-PAR) co

80 The urokinase-type plasminogen activator receptor (u-PAR) fa

81 The urokinase-type plasminogen activator receptor (u-PAR) ha

82 The urokinase-type plasminogen activator receptor (u-PAR) pl

83 Mice lacking the urokinase-type plasminogen activator receptor (u-PAR), a

84 s accompanied by increased expression of the urokinase-type plasminogen activator receptor (uPAR) and

85 adenovirus-mediated expression of antisense urokinase-type plasminogen activator receptor (uPAR) and

86 Because beta-catenin and its target genes urokinase-type plasminogen activator receptor (uPAR) and

87 ocytosis of multiple ligands, transports the urokinase-type plasminogen activator receptor (uPAR) and

88 elial growth factor results in clustering of urokinase-type plasminogen activator receptor (uPAR) and

89 In this study, we identified the urokinase-type plasminogen activator receptor (uPAR) as

90 Urokinase-type plasminogen activator receptor (uPAR) bin

91 Previous studies have indicated that the urokinase-type plasminogen activator receptor (uPAR) can

92 Signaling by urokinase-type plasminogen activator receptor (uPAR) can

93 a serine proteinase that upon binding to the urokinase-type plasminogen activator receptor (uPAR) cat

94 The urokinase-type plasminogen activator receptor (uPAR) dri

95 at in adult mice with a null mutation in the urokinase-type plasminogen activator receptor (uPAR) gen

96 The urokinase-type plasminogen activator receptor (uPAR) has

97 The cell surface urokinase-type plasminogen activator receptor (uPAR) has

98 in the mid-1980s, the cell membrane-anchored urokinase-type plasminogen activator receptor (uPAR) has

99 explore the potential of PET imaging of the urokinase-type plasminogen activator receptor (uPAR) in

100 Moreover, ErbB2-mediated upregulation of urokinase-type plasminogen activator receptor (uPAR) is

101 The urokinase-type plasminogen activator receptor (uPAR) is

102 The urokinase-type plasminogen activator receptor (uPAR) is

103 The urokinase receptor urokinase-type plasminogen activator receptor (uPAR) is

104 The urokinase-type plasminogen activator receptor (uPAR) is

105 ar accumulation of beta-catenin, and induces urokinase-type plasminogen activator receptor (uPAR) mRN

106 ely, increases in steady-state expression of urokinase-type plasminogen activator receptor (uPAR) mRN

107 cells, interaction between vitronectin with urokinase-type plasminogen activator receptor (uPAR) on

108 We have shown previously that the urokinase-type plasminogen activator receptor (uPAR) phy

109 The urokinase-type plasminogen activator receptor (uPAR) pro

110 Expression levels of the urokinase-type plasminogen activator receptor (uPAR) rep

111 e glycosylphosphatidyl-inositol (GPI)-linked urokinase-type plasminogen activator receptor (uPAR) rev

112 We report a new member of the Ly-6/urokinase-type plasminogen activator receptor (uPAR) sup

113 The expression of urokinase-type plasminogen activator receptor (uPAR) was

114 ule (ARM) that is capable of recognizing the urokinase-type plasminogen activator receptor (uPAR), a

115 surface or secreted factors, including CD73, urokinase-type plasminogen activator receptor (uPAR), an

116 se partitioning, co-immunoprecipitation with urokinase-type plasminogen activator receptor (uPAR), an

117 ulin-like growth factor-II, plasminogen, and urokinase-type plasminogen activator receptor (uPAR), to

118 ling pathways downstream of the EGFR and the urokinase-type plasminogen activator receptor (uPAR); ho

119 The urokinase-type plasminogen activator receptor (uPAR, CD8

120 dinated by many receptors, in particular the urokinase-type plasminogen activator receptor (uPAR, CD8

121 18, Mac-1) forms a physical complex with the urokinase-type plasminogen activator receptor (uPAR/CD87

122 through the interaction with a region of the urokinase-type plasminogen activator receptor (uPAR88-92

123 phosphatidylinositol-linked proteins such as urokinase-type plasminogen activator receptor and endoth

124 n of epidermal growth factor receptor and/or urokinase-type plasminogen activator receptor in a varie

125 ive action of cell surface-associated HS and urokinase-type plasminogen activator receptor in the acc

126 ncoding the antimicrobial peptides antigen-6/urokinase-type plasminogen activator receptor related pr

127 r, urokinase-type plasminogen activator, and urokinase-type plasminogen activator receptor, along wit

128 that high basal VEGF, glucose transporter-1, urokinase-type plasminogen activator receptor, and plasm

129 , including plasminogen, thrombomodulin, the urokinase-type plasminogen activator receptor, and to a

130 ated targets of note from this study include urokinase-type plasminogen activator receptor, serine/th

131 the rise of nephropathy biomarkers, soluble urokinase-type plasminogen activator receptor, suPAR and

132 in studies of SLURP (secreted mammalian Ly-6/urokinase-type plasminogen activator receptor-related pr

133 The overexpression of urokinase-type plasminogen activator receptors (uPARs) r

134 Urokinase-type plasminogen activator receptors (uPARs),

135 Single-chain urokinase-type plasminogen activator (scu-PA) possesses

136 asis of the interaction between single-chain urokinase-type plasminogen activator (scuPA) and its rec

137 A recombinant prodrug, single-chain urokinase-type plasminogen activator (scuPA) fused to an

138 precursor of PSA (pro-PSA) and single chain urokinase-type plasminogen activator (scuPA, pro-uPA).

139 e acetate-induced MMP-9 secretion but not of urokinase-type plasminogen activator secretion.

140 in vivo efficacy of mAb16-71 in "human liver urokinase-type plasminogen activator, severe combined im

141 nvestigate the expression of tissue-type and urokinase-type plasminogen activators (t-PA and u-PA, re

142 , cathepsin G, and plasma kallikrein but not urokinase-type plasminogen activator, tissue plasminogen

143 rine proteases thrombin, plasmin, factor Xa, urokinase-type plasminogen activator, tissue plasminogen

144 ty of C4BP, the activation of plasminogen by urokinase-type plasminogen activator to active plasmin w

145 Mice carrying an albumin-urokinase type plasminogen activator transgene (AL-uPA)

146 ytes into the liver of mice that contain the urokinase-type plasminogen activator transgene (uPA) and

147 To test our hypothesis, we directed murine urokinase-type plasminogen activator transgene expressio

148 Human urokinase type plasminogen activator (u-PA) is a member

149 uantitative image analysis for assessment of urokinase-type plasminogen activator (u-PA) and PAI-1.

150 re, 1 min after PHx, but not sham operation, urokinase-type plasminogen activator (u-PA) and u-PA rec

151 Previous studies have shown that activity of urokinase-type plasminogen activator (u-PA) increases ve

152 Gene knockout mice studies indicate that urokinase-type plasminogen activator (u-PA) is important

153 The urokinase receptor (uPAR) binds urokinase-type plasminogen activator (u-PA) through spec

154 tissue-type plasminogen activator (t-PA) and urokinase-type plasminogen activator (u-PA), by modifyin

155 ase trypsin and the highly specific protease urokinase-type plasminogen activator (u-PA).

156 tissue-type plasminogen activator (t-PA) or urokinase-type plasminogen activator (u-PA).

157 r extent) were found to drastically increase urokinase type plasminogen activator (uPA) and matrix me

158 s of normal scars and keloids expressed both urokinase type plasminogen activator (uPA) and plasminog

159 ase (MAPK), cytosolic phospholipase A(2) and urokinase type plasminogen activator (uPA) are required

160 alization and degradation of cell-associated urokinase type plasminogen activator (uPA) through the a

161 h the type of protease (trypsin, thrombin or urokinase type plasminogen activator (uPA)).

162 Urokinase-type plasminogen activator (uPA) activates the

163 tissue-type plasminogen activator (tPA) and urokinase-type plasminogen activator (uPA) activities in

164 Matrix metalloproteinase (MMP), plasmin, and urokinase-type plasminogen activator (uPA) activities we

165 ographic procedure that specifically detects urokinase-type plasminogen activator (uPA) activity in b

166 In untreated animals both tPA and urokinase-type plasminogen activator (uPA) activity was

167 Although maspin does not directly inhibit urokinase-type plasminogen activator (uPA) activity, we

168 (MMP) detection and a colorimetric assay for urokinase-type plasminogen activator (uPA) analysis, we

169 Urokinase-type plasminogen activator (uPA) and 92-kDa ma

170 Here, we show that neurons release urokinase-type plasminogen activator (uPA) and astrocyte

171 specifically inhibit cell surface-associated urokinase-type plasminogen activator (uPA) and fibrinoge

172 nizes the N-terminal growth factor domain of urokinase-type plasminogen activator (uPA) and is expres

173 The high affinity interaction between the urokinase-type plasminogen activator (uPA) and its glyco

174 Pancreatic carcinomas express high levels of urokinase-type plasminogen activator (uPA) and its recep

175 Urokinase-type plasminogen activator (uPA) and its recep

176 Urokinase-type plasminogen activator (uPA) and its recep

177 Interaction between the urokinase-type plasminogen activator (uPA) and its recep

178 The role of urokinase-type plasminogen activator (uPA) and its recep

179 assess whether preoperative plasma levels of urokinase-type plasminogen activator (uPA) and its solub

180 1) and diminishing the enzymatic activity of urokinase-type plasminogen activator (uPA) and matrix me

181 Urokinase-type plasminogen activator (uPA) and plasmin,

182 as reduced and extracellular accumulation of urokinase-type plasminogen activator (uPA) and plasminog

183 d the involvement of p53-mediated changes in urokinase-type plasminogen activator (uPA) and plasminog

184 models focus on the ability of uPAR to bind urokinase-type plasminogen activator (uPA) and promote p

185 tein, p53, and apoptosis with suppression of urokinase-type plasminogen activator (uPA) and the uPA r

186 sly demonstrated that the expression of both urokinase-type plasminogen activator (uPA) and the uPA r

187 Leukocytes express both urokinase-type plasminogen activator (uPA) and the uroki

188 activity capable of cleaving a substrate for urokinase-type plasminogen activator (uPA) and tissue pl

189 rpin inhibitor of the plasminogen activators urokinase-type plasminogen activator (uPA) and tissue pl

190 in, we investigated the upstream activators, urokinase-type plasminogen activator (uPA) and tissue-ty

191 ay regulate cardiac fibrosis by inactivating urokinase-type plasminogen activator (uPA) and ultimatel

192 The urokinase-type plasminogen activator (uPA) and uPA recep

193 F-induced invasion, UM-SCC-1 cells expressed urokinase-type plasminogen activator (uPA) and uPA recep

194 In addition, urokinase-type plasminogen activator (uPA) and uPA recep

195 tor (VLDLr) binds diverse ligands, including urokinase-type plasminogen activator (uPA) and uPA-plasm

196 Urokinase-type plasminogen activator (uPA) and vitronect

197 Mice lacking urokinase-type plasminogen activator (uPA) are highly su

198 s cells produced more of the serine protease urokinase-type plasminogen activator (uPA) as compared w

199 his study identifies the extracellular PAI-1/urokinase-type plasminogen activator (uPA) balance as an

200 Urokinase-type plasminogen activator (uPA) binds to cell

201 Urokinase-type plasminogen activator (uPA) bound to a si

202 crystal structures of trypsin, thrombin, and urokinase-type plasminogen activator (uPA) bound with a

203 Induction of the urokinase-type plasminogen activator (uPA) by hepatocyte

204 tissue-type plasminogen activator (tPA) and urokinase-type plasminogen activator (uPA) decreased und

205 t of peripheral tolerance) actually produced urokinase-type plasminogen activator (uPA) during tolera

206 Sustained urokinase-type plasminogen activator (uPA) expression is

207 Both FGF-2 and phorbol ester-inducible urokinase-type plasminogen activator (uPA) expression re

208 ase C (PKC) activity leading to up-regulated urokinase-type plasminogen activator (uPA) expression.

209 pe plasminogen activator (tPA) gene, and the urokinase-type plasminogen activator (uPA) gene.

210 Of particular importance, urokinase-type plasminogen activator (uPA) has been show

211 tissue-type plasminogen activator (tPA) and urokinase-type plasminogen activator (uPA) in liver repa

212 Urokinase-type plasminogen activator (uPA) induces cell

213 Urokinase-type plasminogen activator (uPA) is a serine p

214 The urokinase-type plasminogen activator (uPA) is a serine p

215 Urokinase-type plasminogen activator (uPA) is a serine p

216 tissue-type plasminogen activator (tPA) and urokinase-type plasminogen activator (uPA) is associated

217 Urokinase-type plasminogen activator (uPA) is expressed

218 Urokinase-type plasminogen activator (uPA) is expressed

219 We have previously demonstrated that urokinase-type plasminogen activator (uPA) is highly exp

220 Urokinase-type plasminogen activator (uPA) is increased

221 hypothesized that Mp-specific expression of urokinase-type plasminogen activator (uPA) is sufficient

222 Urokinase-type plasminogen activator (uPA) is thought to

223 We recently proposed that a proteinase, urokinase-type plasminogen activator (uPA) may be added

224 Urokinase-type plasminogen activator (uPA) participates

225 Plasminogen activation catalyzed by urokinase-type plasminogen activator (uPA) plays an impo

226 The urokinase-type plasminogen activator (uPA) promoter cont

227 We hypothesized that urokinase-type plasminogen activator (uPA) promotes musc

228 The urokinase-type plasminogen activator (uPA) receptor (uPA

229 The interaction of the urokinase-type plasminogen activator (uPA) receptor (uPA

230 ree-domain clamp of Argos also resembles the urokinase-type plasminogen activator (uPA) receptor, whi

231 Genetic absence of the urokinase-type plasminogen activator (uPA) reduces arthr

232 Urokinase-type plasminogen activator (uPA) regulates ang

233 Urokinase-type plasminogen activator (uPA) regulates the

234 ave a significant reduction in expression of urokinase-type plasminogen activator (uPA) relative to t

235 Urokinase-type plasminogen activator (uPA) stimulates MC

236 The urokinase-type plasminogen activator (uPA) system has be

237 Recent studies indicate that binding of the urokinase-type plasminogen activator (uPA) to its high-a

238 The binding of urokinase-type plasminogen activator (uPA) to its recept

239 Binding of the urokinase-type plasminogen activator (uPA) to its recept

240 Binding of urokinase-type plasminogen activator (uPA) to its recept

241 Binding of urokinase-type plasminogen activator (uPA) to its recept

242 Plasminogen activation by urokinase-type plasminogen activator (uPA) was markedly

243 ssays and plasminogen zymography showed that urokinase-type plasminogen activator (uPA) was responsib

244 n with bovine trypsin, rat trypsin and human urokinase-type plasminogen activator (uPA) were investig

245 Interaction of urokinase-type plasminogen activator (uPA) with its rece

246 Urokinase-type plasminogen activator (uPA)(-/-) mice can

247 ession was inversely correlated with that of urokinase-type plasminogen activator (uPA), a prometasta

248 We hypothesized that urokinase-type plasminogen activator (uPA), a protease i

249 a receptor for the plasmin-producing enzyme urokinase-type plasminogen activator (uPA), and can also

250 increased inflammation, increased levels of urokinase-type plasminogen activator (uPA), and greater

251 such as matrix metalloproteinase (MMP)-9 and urokinase-type plasminogen activator (uPA), in human pro

252 ficient cells, which secreted high levels of urokinase-type plasminogen activator (uPA), invaded exte

253 The trypsin-like serine protease, urokinase-type plasminogen activator (uPA), is central i

254 tissue-type plasminogen activator (tPA) and urokinase-type plasminogen activator (uPA), is mediated

255 The plasminogen/plasmin system, urokinase-type plasminogen activator (uPA), its receptor

256 of tissue-type plasminogen activator (tPA), urokinase-type plasminogen activator (uPA), its receptor

257 we found that the expression of epiregulin, urokinase-type plasminogen activator (uPA), matrix metal

258 We report that the urokinase-type plasminogen activator (uPA), one of the c

259 g factors, such as interleukin (IL)-8, IL-6, urokinase-type plasminogen activator (uPA), or uPA recep

260 Tobacco smoke induced the expression of urokinase-type plasminogen activator (uPA), resulting in

261 (such as Factor Xa (FXa), Factor XIa (FXIa), urokinase-type plasminogen activator (uPA), thrombin, an

262 Plasminogen can be activated to plasmin by urokinase-type plasminogen activator (uPA), tissue-type

263 ility of gene-targeted mice deficient in the urokinase-type plasminogen activator (uPA), urokinase re

264 processes by virtue of its interactions with urokinase-type plasminogen activator (uPA), vitronectin

265 site-directed mutant of the serine protease urokinase-type plasminogen activator (uPA), was produced

266 as applied to the screening of inhibitors of urokinase-type plasminogen activator (uPA), which is a p

267 ilencing expression of endogenously produced urokinase-type plasminogen activator (uPA), which is nec

268 In contrast to mammalian urokinase-type plasminogen activator (uPA), which is pro

269 face receptor capable of not only focalizing urokinase-type plasminogen activator (uPA)-mediated fibr

270 closed as potent and selective inhibitors of urokinase-type plasminogen activator (uPA).

271 LAM lesions and angiomyolipomas overexpress urokinase-type plasminogen activator (uPA).

272 the largest difference being the activity of urokinase-type plasminogen activator (uPA).

273 and is required for inducible expression of urokinase-type plasminogen activator (uPA).

274 growth factor (VEGF), isomers of VEGF-A, and urokinase-type plasminogen activator (uPA).

275 Activated lymphocytes express urokinase-type plasminogen activator (uPA).

276 inhibitor 1 (PAI-1) is a major inhibitor of urokinase-type plasminogen activator (uPA).

277 emarkably selective and potent inhibitors of urokinase-type plasminogen activator (uPA).

278 luding tissue-type plasminogen activator and urokinase-type plasminogen activator (uPA).

279 peptide based on consensus cleavage motif of urokinase-type plasminogen activator (uPA).

280 oding tissue plasminogen activator (tPA) and urokinase-type plasminogen activator (uPA).

281 osis in transgenic livers overexpressing the urokinase-type plasminogen activator (uPA).

282 tate ecotin inhibitors for trypsin and human urokinase-type plasminogen activator (uPA).

283 as a suicide substrate for thrombin (Th) and urokinase-type plasminogen activator (uPA).

284 iring the proteolytic cascade of cathepsin B/urokinase-type plasminogen activator (uPA)/matrix metall

285 In addition, we demonstrate that the urokinase-type plasminogen activator (uPA)/uPA receptor

286 urthermore, when tyrosine phosphorylation or urokinase-type plasminogen activator (uPA)/uPAR function

287 ession in mice with targeted deficiencies in urokinase-type plasminogen activator (UPA-/-) and its in

288 Mice deficient in urokinase-type plasminogen activator (uPA-/-) exhibit de

289 The receptor for urokinase-type plasminogen activator (uPAR) plays import

290 sine phosphorylation of beta-catenin, induce urokinase-type plasminogen activator, uPAR, and cyclin D

291 studies have indicated that the receptor for urokinase-type plasminogen activator, uPAR, can form fun

292 amino acid sequence of the chicken and human urokinase-type plasminogen activators (uPAs) revealed th

293 t the active sites of trypsin, thrombin, and urokinase type plasminogen activator (urokinase or uPA)

294 Bound to BBA70, plasminogen activated by urokinase-type plasminogen activator was able to degrade

295 Single-chain urokinase-type plasminogen activator was activated using

296 ould lead to drug-entrapped vascular grafts: urokinase-type plasminogen activator was entrapped withi

297 ctor that expresses a nonsecreted urokinase (urokinase-type plasminogen activator) was transduced int

298 by a compensatory increase in expression of urokinase-type plasminogen activator, which activates uP

299 The PLAU gene within this region encodes urokinase-type plasminogen activator, which converts pla

300 rix metalloproteinase-9 and the secretion of urokinase-type plasminogen activator while increasing ti